Dhofar Governorate, Oman, November 2025 – Dhofar Pharmaceutical Industries Co. LLC has announced the appointment of Dr. Mohammed Hamdan Saif Al-Rubaie as its new Chief Executive Officer, marking a major leadership transition in Oman’s pharmaceutical manufacturing sector.
Dr. Al-Rubaie brings over 26 years of experience in public health, regulatory affairs, and pharmaceutical governance. His distinguished career at the Ministry of Health, Oman—where he served as Director General of the Drug Safety Center and earlier as Director of Drug Control—has made him one of the region’s most respected leaders in drug safety and regulatory excellence.
As CEO, Dr. Al-Rubaie will lead Dhofar Pharmaceutical Industries’ strategic roadmap, focusing on expanding its production capacity, enhancing compliance with international standards, and advancing its portfolio of life-saving medicines and hemodialysis solutions. His deep expertise in policy, safety, and pharmaceutical regulation is expected to strengthen the company’s role as a trusted healthcare partner in Oman and beyond.
Prior to joining Dhofar Pharmaceutical Industries, Dr. Mohammed Hamdan Saif Al-Rubaie spent a decade as Director General of the Drug Safety Center at the Ministry of Health, Oman, where he oversaw national drug monitoring systems, post-marketing surveillance, and policy frameworks to ensure the safety and efficacy of medicinal products across the Sultanate.
Earlier, he served for over 16 years as Director of Drug Control within the Ministry, where he was instrumental in strengthening Oman’s pharmaceutical regulatory landscape. His contributions led to the establishment of modern drug control systems and compliance processes aligned with World Health Organization (WHO) standards.
Dr. Al-Rubaie began his career as a Pharmacist at the Ministry of Health, where his early experience in public sector pharmaceutical services laid the foundation for his lifelong commitment to advancing healthcare quality and patient safety.
He holds a Doctor of Philosophy (PhD) in Pharmacy Administration and Regulatory Affairs from Cardiff University, United Kingdom, and a Master’s degree in Pharmaceutical Sciences with Management Studies from Kingston University, London. His academic background and policy expertise uniquely position him to lead Dhofar Pharma into its next phase of growth and innovation.
About Dhofar Pharmaceutical Industries Co. LLC
Dhofar Pharmaceutical Industries Co. LLC is one of Oman’s leading manufacturers of sterile parenteral preparations, life-saving medicines, and hemodialysis solutions, with a strong focus on addressing the needs of critically ill patients.
The company operates a cGMP-compliant, ISO 9001:2015, and ISO 13485:2016 certified facility approved by the Ministry of Health, Oman. With its culture of innovation, precision, and excellence, Dhofar Pharma is committed to producing high-quality pharmaceutical products that meet international standards and contribute to saving lives across the region.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
